

Remarks

Rejection of the claims under 35 USC §102:

Claims 7, 8, 19, and 20 have been rejected under 35 U.S.C. 102(b) as being anticipated by Tanaka et al. (Chemical and Pharmaceutical Bulletin 1962). Applicants have amended the claims to obviate the rejection. Specifically, Applicants have amended claims 7 and 19 to recite reactive groups delete the term “arylhalide”. In view of the amendment, Applicants request reconsideration of this §102 rejection.

The Examiner's rejections are now believed to be overcome by this response to the Office Action. In view of Applicants' amendment and arguments, it is submitted that claims 7, 8, 19, and 20 should be allowable.

Respectfully submitted,

/Kirk Ekena/  
Kirk Ekena, Reg. No. 56,672  
Mirus Bio Corporation  
505 South Rosa Road  
Madison, WI 53719  
608-238-4400

I hereby certify that this correspondence is being  
transmitted to the USPTO on this date: July 3, 2007.

/Kirk Ekena/  
Kirk Ekena